Daiichi Sankyo and Seattle Genetics are Headed to Court Over an ADC Worth Billions

Interesting. AstraZeneca will love this news

 

Surprised? one time maybe we have a drug looks like we done stole it. way to go Yver the Terrible

 

Can tell you this, HQ is in full panic mode. KW yelling at people and acting crazier than usual

 

Great to see your true colors coming through. Keep it up Matt S, you make us proud.

 

hey Keith! Thanks for the feedback!!

 

of course, feedback, like my stinky beard, is a gift. always here for you, special K

 

yes for dan for past six months no for Keith, he likes a different flavor

 

Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight
By Caroline Simson

Law360 (March 16, 2020, 5:28 PM EDT) -- An arbitrator weighing whether he can adjudicate biotechnology company Seattle Genetics Inc.'s dispute with Daiichi Sankyo Co. Ltd. over cancer drug patents will wait for recommendations from a Delaware court before deciding, according to the Japanese pharmaceutical company.

Daiichi Sankyo told the court on Friday that while the tribunal hasn't formally stayed the arbitration filed by Seattle Genetics, which stems from a dispute arising out of a 2008 collaboration deal, the arbitrator is awaiting the report and recommendations from the court before proceeding.

Daiichi Sankyo has accused Seattle Genetics in the litigation of attempting to "usurp" its rights to certain patents and patent applications relating to antibody drug conjugates technology, which is used to treat patients with cancer.

Seattle Genetics, however, claims that the dispute must be arbitrated under a clause contained in their deal. It's asked the Delaware court to toss the litigation, and how the court comes out on the issue will apparently be of interest to the arbitrator, Daiichi Sankyo told the court.

"[F]or now, the tribunal has declined to further address the briefing before it regarding arbitrability," Daiichi Sankyo said. The company is asking the court in the lawsuit to declare that it owns patents and patent applications relating to allegedly proprietary antibody drug conjugates technology, which is used to target and deliver chemotherapy to cancer cells with less collateral damage to other cells.

Seattle Genetics told the court in November that it had submitted the dispute to the American Arbitration Association, noting that their collaboration agreement stipulated that any dispute arising between the companies "in respect of this agreement" would be arbitrated.

"Because [Daiichi Sankyo]'s ownership claims arise in respect of the agreement, they fall squarely within the terms of the parties' agreement to arbitrate," the company told the court at the time.

Counsel for Seattle Genetics, which develops and commercializes targeted cancer therapies, declined to comment Monday. Counsel for Daiichi Sankyo could not immediately be reached for comment.

Seattle Genetics and Daiichi Sankyo inked a research collaboration agreement in 2006 to develop and evaluate antibody drug conjugates technology, or ADCs, using products developed by both companies. Two years later, the companies agreed that Daiichi Sankyo would have an exclusive worldwide license to use some of Seattle Genetics patent rights and know-how.

Those rights related to Seattle Genetics-developed cytotoxins known as monomethyl Auristatin E, or MMAE, and monomethyl Auristatin F, or MMAF.

Daiichi Sankyo terminated the deal in April 2015 after it failed to discover a clinical drug candidate using Seattle Genetics' patented technology.

More than four years later, Seattle Genetics sent a letter to Daiichi Sankyo claiming that certain drug conjugation technology used in one of its drug candidates fell under the collaboration agreement. But Daiichi Sankyo said it independently developed the technology used in the drug.

That technology is designed to deliver the cytotoxin DXd through a unique metabolic pathway, but DXd isn't derived from MMAE or MMAF, the suit claims.

Daiichi Sankyo's ADC technology targets and delivers chemotherapy to cancer cells so as to minimize systemic exposure to the toxic chemicals used during the treatment. The company says it's developed multiple ADCs, and that its investigational ADC program currently consists of seven novel proprietary ADCs.

Read more at: Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight - Law360

 

Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight

By Caroline Simson

Law360 (March 16, 2020, 5:28 PM EDT) -- An arbitrator weighing whether he can adjudicate biotechnology company Seattle Genetics Inc.'s dispute with Daiichi Sankyo Co. Ltd. over cancer drug patents will wait for recommendations from a Delaware court before deciding, according to the Japanese pharmaceutical company.

Daiichi Sankyo told the court on Friday that while the tribunal hasn't formally stayed the arbitration filed by Seattle Genetics, which stems from a dispute arising out of a 2008 collaboration deal, the arbitrator is awaiting the report and recommendations from the court before proceeding.

Daiichi Sankyo has accused Seattle Genetics in the litigation of attempting to "usurp" its rights to certain patents and patent applications relating to antibody drug conjugates technology, which is used to treat patients with cancer.

Seattle Genetics, however, claims that the dispute must be arbitrated under a clause contained in their deal. It's asked the Delaware court to toss the litigation, and how the court comes out on the issue will apparently be of interest to the arbitrator, Daiichi Sankyo told the court.

"[F]or now, the tribunal has declined to further address the briefing before it regarding arbitrability," Daiichi Sankyo said. The company is asking the court in the lawsuit to declare that it owns patents and patent applications relating to allegedly proprietary antibody drug conjugates technology, which is used to target and deliver chemotherapy to cancer cells with less collateral damage to other cells.

Seattle Genetics told the court in November that it had submitted the dispute to the American Arbitration Association, noting that their collaboration agreement stipulated that any dispute arising between the companies "in respect of this agreement" would be arbitrated.

"Because [Daiichi Sankyo]'s ownership claims arise in respect of the agreement, they fall squarely within the terms of the parties' agreement to arbitrate," the company told the court at the time.

Counsel for Seattle Genetics, which develops and commercializes targeted cancer therapies, declined to comment Monday. Counsel for Daiichi Sankyo could not immediately be reached for comment.

Seattle Genetics and Daiichi Sankyo inked a research collaboration agreement in 2006 to develop and evaluate antibody drug conjugates technology, or ADCs, using products developed by both companies. Two years later, the companies agreed that Daiichi Sankyo would have an exclusive worldwide license to use some of Seattle Genetics patent rights and know-how.

Those rights related to Seattle Genetics-developed cytotoxins known as monomethyl Auristatin E, or MMAE, and monomethyl Auristatin F, or MMAF.

Daiichi Sankyo terminated the deal in April 2015 after it failed to discover a clinical drug candidate using Seattle Genetics' patented technology.

More than four years later, Seattle Genetics sent a letter to Daiichi Sankyo claiming that certain drug conjugation technology used in one of its drug candidates fell under the collaboration agreement. But Daiichi Sankyo said it independently developed the technology used in the drug.

That technology is designed to deliver the cytotoxin DXd through a unique metabolic pathway, but DXd isn't derived from MMAE or MMAF, the suit claims.

Daiichi Sankyo's ADC technology targets and delivers chemotherapy to cancer cells so as to minimize systemic exposure to the toxic chemicals used during the treatment. The company says it's developed multiple ADCs, and that its investigational ADC program currently consists of seven novel proprietary ADCs.

 

Let the Truth be told! Seattle Genetics (Seagen) - Texas Federal court

Oct-2020

PRAYER FOR RELIEF WHEREFORE, Seagen respectfully requests the following relief:
a. Judgment in Seagen’s favor against Daiichi Sankyo (DSC) that DSC infringed one or more valid and enforceable claims of the ’039 patent;

b. A finding that DSC’s infringement was willful;

c. An award of damages to Seagen in an amount to be proven at trial, including lost profits but in no event less than a reasonable royalty, as well as pre-judgment and post-judgment interest at the maximum rate permitted by law;

d. An award of attorney fees and enhancement of any damages by virtue of the exceptional nature of this case under 35 U.S.C. § 285;

e. A running royalty; and

f. Such other relief as the Court deems just and proper. DEMAND FOR JURY TRIAL Seagen hereby demands trial by jury of all claims and issues so triable presented in this Complaint.

Full COMPLAINT FOR PATENT INFRINGEMENT can be found

https://www.seagen.com/assets/pdfs/news/seagen_inc_complaint_against_daiichi_sankyo_coltd..pdf

 

Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo


- Jury Upholds Validity of Asserted Claims of the Patent, Finds Willful Infringement and Issues Past Damages Award of $41.82 Million -

- Seagen to Request Royalty on Future U.S. Sales of Enhertu® Through the Life of the Patent -

- Separate Arbitration Proceedings with Daiichi Sankyo Remain Ongoing with a Decision Expected by Mid-2022 -

April 08, 2022 03:23 PM Eastern Daylight Time
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that a jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) infringed Seagen’s U.S. Patent No. 10,808,039 by selling in the United States its Enhertu® product (trastuzumab deruxtecan; DS-8201). Seagen was awarded damages of $41.82 million for past infringement of the patent. In addition, Seagen will request additional royalty payments for future sales of Enhertu in the United States through the life of the patent.

 

Wow if you waited a few more days this could have been months old news

 

Sopranos Pharna

 

yea but you dsi folks are a bit slow... we need to spoon feed you slowly with information otherwise you will dribble all over

 

This is the filthiest company in the industry.

 

Ginzo Pharma

 

Well done daiichi

 

SMLM - “Stolen Molecule’s Lives Matter “

 

Yes